New Zealand markets closed

Twist Bioscience Corporation (TWST)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
53.90+0.34 (+0.63%)
At close: 04:00PM EDT
53.90 0.00 (0.00%)
After hours: 05:07PM EDT

Twist Bioscience Corporation

681 Gateway Boulevard
South San Francisco, CA 94080
United States
800 719 0671

IndustryDiagnostics & Research
Full-time employees919

Key executives

NameTitlePayExercisedYear born
Dr. Emily Marine Leproust Ph.D.Co-Founder, Chairman & CEO1.37M153.71k1973
Dr. Patrick John Finn Ph.D.President & COO943.94kN/A1972
Ms. Paula GreenSenior Vice President of Human Resources618.48kN/A1968
Dr. William Charles Banyai Ph.D.Senior VP of Advanced Development, GM of Data Storage & Director711.34kN/A1955
Mr. Adam LaponisChief Financial OfficerN/AN/A1977
Mr. Robert F. WernerVP & Chief Accounting OfficerN/AN/A1973
Mr. Siyuan ChenChief Technology OfficerN/AN/AN/A
Dr. Aaron K. Sato Ph.D.Chief Scientific OfficerN/AN/AN/A
Mr. Chet GandhiChief Information OfficerN/AN/AN/A
Mr. Dennis ChoSenior VP, Chief Legal Officer & Corporate Secretary537.93kN/A1971
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Corporate governance

Twist Bioscience Corporation’s ISS governance QualityScore as of 1 July 2024 is 7. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.